InvivoGen Insight Newsletters

Latest Insight Newsletter - Winter 2015/16

InvivoGen Insight Winter 2014/15

- Antibody Isotype Families

   - Knockout Reporter Cell Lines

   - Reporter Detection Reagents

   - Endotoxin-free Selective Antibiotics

- Review: Improving the efficacy of clinical antibodies

Monoclonal antibodies (mAbs) have shown considerable success as cancer therapeutics and the number of anticancer mAbs in clinical use or under investigation has dramatically increased in recents years. However, there remains much room for improvement. Therapeutic antibodies act mainly by directly targeting tumor cells or by targeting immune cells in the tumor microenvironment....

Previous Issues

Winter 2015/16 - Improving the efficacy of clinical antibodies

Winter 2014/15 - Inflammasome activation: a matter of caspases

Winter 2013/14 - Deciphering the STING Paradox

Fall 2013 - β-Glucans: bittersweet ligands of Dectin-1

Spring 2013 - Multi-TLR Agonists: Potential for Therapeutic Success

Fall 2012 - Cytosolic DNA Sensors (CDSs): a STING in the tail

Summer 2012 - Lucia™, a novel secreted luciferase

Winter 2011 - Mycoplasma Detection and Elimination

Summer 2011 - Antibody and Vaccine adjuvants

Fall 2010 - Cytosolic dsDNA Sensors (CDS)

Spring 2010 - Lentiviral Vector Production


Older Issues

Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2015 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "www.invivogen.com".